Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albertsson

Showing results (771-780 of 859) with videos related to

Pageof 86
Sort By:
Clinical Endocrinology|August 5, 2006
Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database)Maria E Craig, Christopher T Cowell, Pontus Larsson, et al.
The Journal of Clinical Endocrinology and Metabolism|January 13, 2012
Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE studyLars Sävendahl, Marc Maes, Kerstin Albertsson-Wikland, et al.
Immunology and Cell Biology|May 13, 2009
Human NK cell lines migrate differentially in vitro related to matrix interaction and MMP expressionKarin Edsparr, Bengt R Johansson, Ronald H Goldfarb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2008
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancerB Glimelius, H Sørbye, L Balteskard, et al.
The Journal of Clinical Endocrinology and Metabolism|November 13, 2008
Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short statureBerit Kriström, A Stefan Aronson, Jovanna Dahlgren, et al.
Acta Oncologica (Stockholm, Sweden)|December 8, 2005
Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy GroupBengt Glimelius, Olav Dahl, Björn Cedermark, et al.
International Journal of Radiation Oncology, Biology, Physics|October 14, 2015
Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer PatientsElin Cederkrantz, Håkan Andersson, Peter Bernhardt, et al.
The Journal of Clinical Endocrinology and Metabolism|October 15, 2003
The mathematical model for total pubertal growth in idiopathic growth hormone (GH) deficiency suggests a moderate role of GH doseMichael B Ranke, Anders Lindberg, David D Martin, et al.
The Journal of Pediatrics|December 1, 1992
Congenital idiopathic growth hormone deficiency associated with prenatal and early postnatal growth failure. The International Board of the Kabi Pharmacia International Growth StudyP D Gluckman, A J Gunn, A Wray, et al.
Acta Paediatrica (Oslo, Norway : 1992)|January 1, 1995
Thyroid autoantibodies, Turner's syndrome and growth hormone therapyS A Ivarsson, U B Ericsson, K O Nilsson, et al.
Pageof 86

Showing results (771-780 of 859) with videos related to

Sort By:
Pageof 86
Clinical Endocrinology|August 5, 2006
Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database)Maria E Craig, Christopher T Cowell, Pontus Larsson, et al.
The Journal of Clinical Endocrinology and Metabolism|January 13, 2012
Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE studyLars Sävendahl, Marc Maes, Kerstin Albertsson-Wikland, et al.
Immunology and Cell Biology|May 13, 2009
Human NK cell lines migrate differentially in vitro related to matrix interaction and MMP expressionKarin Edsparr, Bengt R Johansson, Ronald H Goldfarb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2008
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancerB Glimelius, H Sørbye, L Balteskard, et al.
The Journal of Clinical Endocrinology and Metabolism|November 13, 2008
Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short statureBerit Kriström, A Stefan Aronson, Jovanna Dahlgren, et al.
Acta Oncologica (Stockholm, Sweden)|December 8, 2005
Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy GroupBengt Glimelius, Olav Dahl, Björn Cedermark, et al.
International Journal of Radiation Oncology, Biology, Physics|October 14, 2015
Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer PatientsElin Cederkrantz, Håkan Andersson, Peter Bernhardt, et al.
The Journal of Clinical Endocrinology and Metabolism|October 15, 2003
The mathematical model for total pubertal growth in idiopathic growth hormone (GH) deficiency suggests a moderate role of GH doseMichael B Ranke, Anders Lindberg, David D Martin, et al.
The Journal of Pediatrics|December 1, 1992
Congenital idiopathic growth hormone deficiency associated with prenatal and early postnatal growth failure. The International Board of the Kabi Pharmacia International Growth StudyP D Gluckman, A J Gunn, A Wray, et al.
Acta Paediatrica (Oslo, Norway : 1992)|January 1, 1995
Thyroid autoantibodies, Turner's syndrome and growth hormone therapyS A Ivarsson, U B Ericsson, K O Nilsson, et al.
Pageof 86